The Oncologic Drug Advisory Committee (OADC) will meet to discuss the appropriate approach for phosphatidylinositol-3-kinase inhibitors currently under development in patients with hematologic malignancies and whether randomized data should be required to support a demonstration of substantial evidence of effectiveness and that the drug is safe for its intended use in the proposed population.